Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGoXIM
- Development stage
- Preclinical
- Lead developer
- TherapyX
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
NGoXIM is an investigational intranasal prophylactic vaccine intended to prevent gonorrhea caused by Neisseria gonorrhoeae. Developed by Therapyx with Intravacc, it combines gonococcal outer-membrane vesicles containing bacterial surface antigens with sustained-release microspheres encapsulating recombinant human interleukin-12. The IL-12 component is intended to enhance mucosal and systemic Th1-biased immune responses to the gonococcal antigens. Preclinical mouse studies reported serum and mucosal anti-gonococcal antibody responses, increased interferon-gamma production by CD4-positive T cells, and resistance to challenge with diverse gonococcal strains following intranasal administration.
- Brand names
- Avacc 11Avacc11Avacc-11
- Other names
- gonorrhea vaccine (Intravacc)NGoXIM vaccine
02
Targets
Beyond the preview
Go deeper on NGoXIM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGoXIM.